CN1436234A - 用于前列腺癌治疗和诊断的组合物及方法 - Google Patents

用于前列腺癌治疗和诊断的组合物及方法 Download PDF

Info

Publication number
CN1436234A
CN1436234A CN01806526A CN01806526A CN1436234A CN 1436234 A CN1436234 A CN 1436234A CN 01806526 A CN01806526 A CN 01806526A CN 01806526 A CN01806526 A CN 01806526A CN 1436234 A CN1436234 A CN 1436234A
Authority
CN
China
Prior art keywords
seq
sequence
cdna sequence
mensuration
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01806526A
Other languages
English (en)
Chinese (zh)
Inventor
徐江春
D·C·迪隆
J·L·密特查姆
S·L·哈洛克
蒋宇秋
S·G·里德
M·D·卡洛斯
G·R·范戈
C·H·戴
M·W·雷特
J·A·斯托尔克
Y·A·W·斯凯奇
王爱君
M·J·米格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of CN1436234A publication Critical patent/CN1436234A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
CN01806526A 2000-01-14 2001-01-16 用于前列腺癌治疗和诊断的组合物及方法 Pending CN1436234A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48367200A 2000-01-14 2000-01-14
US09/483,672 2000-01-14

Publications (1)

Publication Number Publication Date
CN1436234A true CN1436234A (zh) 2003-08-13

Family

ID=23921037

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01806526A Pending CN1436234A (zh) 2000-01-14 2001-01-16 用于前列腺癌治疗和诊断的组合物及方法

Country Status (16)

Country Link
EP (1) EP1261708A2 (ko)
JP (1) JP2003528591A (ko)
KR (1) KR20030016217A (ko)
CN (1) CN1436234A (ko)
AU (1) AU3447401A (ko)
BR (1) BR0107643A (ko)
CA (1) CA2397741A1 (ko)
CZ (1) CZ20022756A3 (ko)
HU (1) HUP0203968A3 (ko)
IL (1) IL150732A0 (ko)
MX (1) MXPA02006934A (ko)
NO (1) NO20023402L (ko)
PL (1) PL356908A1 (ko)
RU (1) RU2002121771A (ko)
WO (1) WO2001051633A2 (ko)
ZA (1) ZA200206400B (ko)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104357451A (zh) * 2014-12-02 2015-02-18 广州市番禺区中心医院 针对dd3基因的小干扰rna及其表达载体构建与应用
CN108998418A (zh) * 2012-05-25 2018-12-14 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
CN110325205A (zh) * 2016-12-22 2019-10-11 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CN114250238A (zh) * 2021-11-26 2022-03-29 北京航空航天大学 基因编码的神经元发育调控多肽及其应用

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO1998045420A1 (en) 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6861215B1 (en) 1998-05-21 2005-03-01 Diadexus, Inc. Method of diagnosing, monitoring, and staging prostate cancer
JP4855577B2 (ja) 1998-06-01 2012-01-18 アジェンシス，インコーポレイテッド ヒト癌で発現される新規蛇行性膜貫通抗原およびその使用
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
ES2260059T3 (es) 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
DE60033583T2 (de) * 1999-10-07 2007-09-13 Corixa Corp. CSC, Wilmington Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
AU2001249549A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DK2133100T3 (da) 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
US20020142284A1 (en) * 2000-07-13 2002-10-03 Debasish Raha Methods of identifying renal protective factors
CA2417671A1 (en) * 2000-07-28 2002-02-07 Ulrich Wissenbach Trp8, trp9 and trp10, novel markers for cancer
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2005504513A (ja) * 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP2287186B1 (en) * 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7371841B2 (en) 2002-01-25 2008-05-13 Regents Of The University Of California Methods of modulating cold sensory perception
DE10215321A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Trp-p8 Splice Varianten und regulatorische RNA
CN100360558C (zh) * 2002-06-11 2008-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
DE10234901A1 (de) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
BRPI0418766B8 (pt) 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
EP1916298B1 (en) * 2005-06-14 2011-12-28 Dnavec Corporation Methods for producing monoclonal antibodies
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520566D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN110494452B (zh) 2017-04-03 2023-08-25 豪夫迈·罗氏有限公司 结合steap-1的抗体
CN110988348B (zh) * 2019-11-06 2022-07-05 北京九强生物技术股份有限公司 游离前列腺特异性抗原检测试剂盒及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
TR199902053T2 (xx) * 1997-02-25 2000-04-21 Corixa Corporation Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
ATE302414T1 (de) * 1997-02-25 2005-09-15 Corixa Corp Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
KR20070112860A (ko) * 1998-07-14 2007-11-27 코릭사 코포레이션 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
JP2004537252A (ja) * 1999-11-12 2004-12-16 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108998418A (zh) * 2012-05-25 2018-12-14 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
CN104357451A (zh) * 2014-12-02 2015-02-18 广州市番禺区中心医院 针对dd3基因的小干扰rna及其表达载体构建与应用
CN104357451B (zh) * 2014-12-02 2016-09-21 广州市番禺区中心医院 针对dd3基因的小干扰rna及其表达载体构建与应用
CN110325205A (zh) * 2016-12-22 2019-10-11 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
CN114250238A (zh) * 2021-11-26 2022-03-29 北京航空航天大学 基因编码的神经元发育调控多肽及其应用
CN114250238B (zh) * 2021-11-26 2023-08-25 北京航空航天大学 基因编码的神经元发育调控多肽及其应用

Also Published As

Publication number Publication date
BR0107643A (pt) 2003-06-10
PL356908A1 (en) 2004-07-12
KR20030016217A (ko) 2003-02-26
NO20023402L (no) 2002-08-29
HUP0203968A3 (en) 2004-09-28
AU3447401A (en) 2001-07-24
HUP0203968A2 (hu) 2003-03-28
CZ20022756A3 (cs) 2003-02-12
RU2002121771A (ru) 2004-03-10
JP2003528591A (ja) 2003-09-30
WO2001051633A2 (en) 2001-07-19
CA2397741A1 (en) 2001-07-19
WO2001051633A9 (en) 2002-10-31
IL150732A0 (en) 2003-02-12
ZA200206400B (en) 2004-01-21
EP1261708A2 (en) 2002-12-04
NO20023402D0 (no) 2002-07-15
WO2001051633A3 (en) 2002-06-20
MXPA02006934A (es) 2003-01-28

Similar Documents

Publication Publication Date Title
CN1436234A (zh) 用于前列腺癌治疗和诊断的组合物及方法
AU762812B2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
US6664377B1 (en) Compounds for immunotherapy of prostate cancer and methods for their use
US6329505B1 (en) Compositions and methods for therapy and diagnosis of prostate cancer
CN1195851C (zh) 用于前列腺癌免疫疗法的化合物及其用途
US6261562B1 (en) Compounds for immunotherapy of prostate cancer and methods for their use
CA2391369A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CA2403909A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CA2446788A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
US20020081580A1 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
US6395278B1 (en) Prostate specific fusion protein compositions
CN1367829A (zh) 用于肺癌治疗和诊断的组合物和方法
TWI250208B (en) Compositions and methods for therapy and diagnosis of prostate cancer
US6613872B1 (en) Compounds for immunotherapy of prostate cancer and methods for their use
US6657056B2 (en) Compounds for immunotherapy of prostate cancer and methods for their use
MXPA01000432A (en) Compositions and methods for therapy and diagnosis of prostate cancer
US20020182596A1 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
TW200815476A (en) Compositions and methods for therapy and diagnosis of prostate cancer
TWI228593B (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
CN1690077A (zh) 用于前列腺癌免疫疗法的化合物及其用途
MXPA99007858A (en) Compounds for immunodiagnosis of prostate cancer and methods for their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication